Tamtam Try Tamtam free
Haleon logo

Haleon account plan

Improve everyday health

At a glance

Haleon is a consumer health company behind Sensodyne, Centrum, Advil and Panadol, with £11,030m of 2025 revenue and about 24,000 employees.

Haleon is a consumer health company, spun off from GSK in 2022 and listed in London with American Depositary Shares in New York. It sells oral health, vitamins and supplements, pain relief, respiratory, digestive and skin health products under brands such as Sensodyne, parodontax, Centrum, Advil, Panadol, Voltaren and Otrivin, reaching 1.4bn consumers in a market it sizes at c.£200bn. FY2025 revenue was £11,030m (organic +3.0%), adjusted operating profit £2,526m (22.9% margin) and free cash flow £1,913m, with an average workforce of about 24,000. In 2025, EMEA & LatAm brought £4,592m of revenue, North America £3,866m and APAC £2,572m; from 2026 it reports North America, Europe, APAC and International. Brian McNamara is CEO.

Business units

Strategic priorities

Win as One: 1bn more consumers by 2030
The strategy launched in May 2025 aims to reach 1bn more consumers by 2030 and deliver industry-leading shareholder returns, through innovation-led premiumisation and reaching lower-income consumers, such as Rs. 20 Sensodyne packs in more than 500,000 Indian stores.
Return to stronger volume growth
After Q3 2026 growth below expectations, the CEO's key priority is "to drive stronger volume growth" and get back to the medium-term guidance of 4-6% organic revenue growth.
Four commercial priorities for 2027
Scale innovation (38 new Centrum claims unlocked with AI tools), an AI-enhanced perfect store model in 20 markets by Q1 2027, revenue growth management analytics in 16 of the top 20 markets, and more effective A&P spending.
Supply chain productivity
£800m gross supply chain savings by 2030 and 50-80bps a year of gross margin expansion; SKUs were cut c.27% and formulations c.26% since the start of 2024, with over 180 robots added in 18 months.
New operating model
Announced in January 2026: a Chief Growth Officer over categories, marketing and a new Commercial Excellence team, and consolidation from three regions and 14 business units to six operating units, with c.£175m-200m of annualised gross savings over two years.

Latest results

In Q3 2026 (three months to 30 September), revenue was £2,868m, up 2.6% organically (price +2.1%, volume/mix +0.5%), which management said was below expectations. Oral Health grew 8.8% and International 6.9%, while Respiratory Health fell 2.0% and Europe 0.6%. In H1 2026, revenue was £5,602m (organic +2.6%) and adjusted operating profit £1,364m, up 8.2% at constant currency, with a 24.3% margin. Haleon cut its FY2026 organic revenue growth guidance to around 2.5% from 3-5%, citing the suspension of Centrum OTC imports into China (c.£75m of FY2025 revenue) and a Brazil go-to-market change, but kept high single-digit adjusted operating profit growth.

Investments and deals

Oral health manufacturing in India and China
c.£175m for a new oral health plant in India, opening 2028, and c.£65m for an oral health plant in China.
Microsoft partnership
A five-year strategic partnership with Microsoft announced with the H1 2026 results, alongside AI tools for claims, perfect store and pricing analytics.
Share buybacks
£1.1bn was returned to shareholders in 2025; a further £500m buyback announced in Q3 2026 brings 2026 shareholder returns to £1.6bn.
R&D facility and China joint venture
c.£200m is being invested in a new R&D facility, and Haleon bought the remaining 12% of its TSKF joint venture in China; bolt-on acquisitions remain the M&A focus.

Challenges and risks

Weak cold and flu season
US cough, cold and flu category consumption fell 8% in Q3 2026, and Respiratory Health declined in 2025 and 2026.
Centrum disruption in China
A raw material classification change forced Haleon to stop importing for OTC-registered Centrum products in China, a 50bps drag on Q3 group growth expected to last through Q4 and 2027.
Weak consumer demand
The CEO says US consumers are "quite reticent" amid tariffs and the war in Iran, and Europe faces a weak, value-seeking consumer, with Q3 2026 volume/mix down 2.7% there.
Execution of the operating model change
Restructuring costs for the new operating model cut H1 2026 reported operating profit by 2.6%, and the risk factors note no assurance the model will deliver the expected benefits.
Geopolitical and ingredient risks
Principal risks include the US-China relationship between its two largest markets, tariffs, trusted ingredients and supply chain resilience.

What leadership says

“we're not satisfied with the broader group growth rate and the consistency of our performance in recent quarters.”

Brian McNamara, Chief Executive Officer · Q3 2026 results call, 29 October 2026

“the last phase for me is to create a truly agile, performance-focused, consumer-centric company.”

Brian McNamara, Chief Executive Officer · Semafor, The CEO Signal, 25 September 2026

“on the premium side, there's tremendous opportunity. On the low-income side, there's tremendous opportunity. In the middle, there's quite a bit of stress and pressure on the consumer.”

Brian McNamara, Chief Executive Officer · Semafor, The CEO Signal, 25 September 2026

“for the first time since separation, we are now in line with our leverage target of around 2.5 times from a starting point of four times.”

Dawn Allen, Chief Financial Officer · Q3 2026 results call, 29 October 2026

Where a supplier can help

Retail execution and AI tooling
The AI-enhanced perfect store model rolling out to 20 markets and revenue growth management analytics in 16 of the top 20 markets create needs for retail execution, pricing and promotion analytics tools.
Marketing effectiveness and digital commerce
Haleon is shifting A&P toward precise audiences, social content, creators and digital commerce (20% of US revenue), so media, retail media and creator-marketing partners fit the A&P effectiveness priority.
Supply chain automation and savings
The £800m supply chain savings target, SKU simplification and new plants in India and China call for automation, robotics and manufacturing suppliers.
Operating model transformation
Moving from 14 business units to six operating units, with a new Commercial Excellence team, opens doors for consulting, change management and commercial systems support.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Haleon?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Haleon

What does Haleon do?

Haleon makes consumer health products in oral health, vitamins and supplements, pain relief, respiratory, digestive and skin health, under brands including Sensodyne, Centrum, Advil, Panadol, Voltaren and Otrivin.

What is Haleon's revenue?

FY2025 revenue was £11,030m with adjusted operating profit of £2,526m. H1 2026 revenue was £5,602m, and FY2026 organic growth is now guided at around 2.5%.

How many employees does Haleon have?

Haleon had an average workforce of about 24,000 in 2025.

Who leads Haleon?

Brian McNamara is CEO, Dawn Allen is CFO and Vindi Banga has been Chair since 1 January 2026.

What is Haleon's strategy?

Its Win as One strategy aims to reach 1bn more consumers by 2030 and deliver industry-leading shareholder returns through premium innovation, reach to lower-income consumers, supply chain productivity and a new six-unit operating model.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)